Virbac stock holds near analyst consensus as outlook confirmed

Virbac stock (ISIN FR0000031577) is trading close to the EUR 413 analyst consensus price target as of mid-September 2026, positioning the animal health group near the middle of the current valuation range for the shares. As Simply Wall St reported on September 20, 2026, analysts covering Virbac see fair value between EUR 360 and EUR 440 per share, with the EUR 413 consensus roughly in the center of that corridor.

Analyst targets frame Virbac stock valuation

According to ad-hoc-news.de summarizing Simply Wall St data on September 20, 2026, the most bullish analyst on Virbac stock currently sets a price target of EUR 440 per share, while the most cautious stands at EUR 360 per share. With the consensus at EUR 413, that implies the midpoint is EUR 53 above the lower end and EUR 27 below the upper end of the range, quantifying the spread of views in concrete numbers.

Within this corridor, the EUR 413 consensus target indicates potential upside of about 14.7 percent from the EUR 360 bearish target and downside of roughly 6.1 percent versus the EUR 440 bullish estimate, giving investors a numerical sense of how far the stock could move before the valuation picture would be considered stretched either way. As Simply Wall St notes in the same overview, this EUR 80 spread between the extremes shows that professionals can differ by more than 20 percent on fair value even when they agree on Virbac’s business model and long term growth drivers in animal health.

Recent earnings underpin stable forecasts

As ad-hoc-news.de reports on September 20, 2026, Virbac’s latest quarterly figures prompted analysts to leave the EUR 413 consensus target unchanged, a sign that both revenue and earnings trends largely matched expectations for fiscal year 2026. The summary of the first quarter release highlights that Virbac generated solid growth in its animal health portfolio while maintaining profitability, which, in turn, allowed the company to confirm its outlook for the year.

According to the same Simply Wall St based overview, the stability of the consensus after the first quarter reflects a view that Virbac is broadly executing its strategy in line with earlier models for fiscal 2026, with no major positive or negative surprise large enough to require an overhaul of estimates. For investors, this kind of steady execution often matters as much as headline growth rates, because it influences the confidence analysts place in their longer term cash flow projections and valuation multiples.

Stock trades around consensus level

On its primary listing at Euronext Paris under the ticker VIRP, Virbac stock recently changed hands close to the EUR 413 analyst consensus target as of the last completed trading day in mid-September 2026, leaving the shares positioned between the EUR 360 cautious and EUR 440 optimistic valuation markers described by Simply Wall St. This means the current market price is already near the level where analysts, on average, see fair value, while still leaving numerical room to the downside and upside in relation to individual price targets.

For retail investors, the key takeaway is that Virbac stock is presently valued near consensus, backed by recent quarterly results that supported the company’s confirmed outlook. The combination of a clearly defined analyst range, a midpoint of EUR 413 per share and a trading level close to that midpoint gives a quantified framework for thinking about risk and opportunity: the stock would have to fall roughly EUR 53 to align with the most cautious view, or rise about EUR 27 to reach the most optimistic target, based on the current set of published estimates.

Virbac shares and current market data

As of the last completed trading day in mid-September 2026, Virbac stock on Euronext Paris remains supported by the company’s recent confirmation of its outlook and by analyst valuations clustered around EUR 413 per share. While intraday moves will continue to reflect broader market sentiment and sector trends in animal health, the current positioning of the price within the EUR 360 to EUR 440 range shows that the market is broadly aligned with the existing analyst consensus rather than pricing in an extreme scenario.

More news and analyses on Virbac stock